Trial Profile

A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
Indications Multiple myeloma
Focus Therapeutic Use
Sponsors Bristol-Myers Squibb

Most Recent Events

25 May 2022 Status changed from completed to discontinued.
11 Jan 2022 Status changed from active, no longer recruiting to completed.
12 Jul 2020 Results (n=420) from NCT01241292, NCT0139396415, NCT01441973,NCT022728038, NCT0123979718, evaluating PPK analysis of elotuzumab (including data from Japanese patients n=77) with multiple myeloma, published in the Journal of Clinical Pharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com